AT845 - Emerging Drug Insight and Market Forecast – 2030

AT845 - Emerging Drug Insight and Market Forecast – 2030

  • September 2020 •
  • 50 pages •
  • Report ID: 5967843 •
  • Format: PDF
“AT845 - Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Pompe Disease in 7 Major Markets. A detailed picture of the AT845 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary
AT845 is intended to provide long-term production of an enzyme called acid alpha-glucosidase (GAA), required to break down glycogen into glucose, which is used by cells to produce energy. Pompe disease is caused by mutations in the GAA gene, which impair production or activity of the enzyme. Audentes’ gene therapy contains modified, harmless viral vectors carrying the GAA gene, which is expected to raise GAA enzyme levels, subsequently easing Pompe disease’s symptoms. The drug is currently in phase I/II stage of development.

Scope of the report
The report provides insights into:
• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around AT845.
• The report contains forecasted sales for AT845 till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Pompe Disease.
• The report also features the SWOT analysis with analyst insights and key findings of AT845.

Methodology
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by our team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AT845 Analytical Perspective
• In-depth AT845 Market Assessment
This report provides a detailed market assessment of AT845 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

• AT845 Clinical Assessment
The report provides the clinical trials information of AT845 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights
• In the coming years, the market scenario for Pompe Disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence AT845 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Pompe Disease are giving market competition to AT845 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of AT845.
• Our in-depth analysis of the forecasted sales data of AT845 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AT845.

Key Questions
• Which company is developing AT845 along with the phase of the clinical study?
• What is the technology utilized in the development of AT845?
• What is the product type, route of administration and mechanism of action of AT845?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AT845 development?
• What are the key designations that have been granted to AT845?
• What is the forecasted market scenario of AT845?
• What is the history of AT845 and what is its future?
• What is the forecasted sales of AT845 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to AT845?
• Which are the late-stage emerging therapies under development for the treatment of the PPD?